Clinical Trial Update: Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is testing Erdafitinib for recurrent glioma (including WHO grades 2–4) that has progressed after prior treatment; recruitment is ongoin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma
• Glioma Who

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Glioma, Recurrent WHO Grade 2 Glioma | Phase 2 | Status: RECRUITING